The long-term model described in this paper indicated that the costs associated with delaying progression of MS by treatment with IFNß-1a decrease over time, reaching a level of around £453 or 732 per ...

Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...

The variability in functional performance within and between levels of disability measured by the Expanded Disability Status Scale (EDSS) call into question the reliability of the EDSS itself, ...

Confirmed disability progression is often used as a study endpoint to predict progression, but a new report says its predictive value may be overblown. A new analysis suggests a common measure of ...

We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population. We developed a ...